

References

I-36

1. Aloxi® (palonosetron HCl) injection for intravenous use [package insert]. Helsinn Therapeutics, Inc. Iselin, NJ. 04/2020.
2. Micromedex DrugDex Compendium®. 2024.Palonosetron.
3. Clinical Pharmacology™ Compendium. 2024.Tampa FL: Gold Standard, Inc. Palonosetron.
4. National Comprehensive Cancer Network (NCCN). Palonosetron hydrochloride. NCCN Drugs & Biologics Compendium®. 2024.
5. Bungo Saito, Hidetoshi Nakashima, Maasa Abe, et al. Efficacy of palonosetron to prevent delayed nausea and vomiting in non-Hodgkin's lymphoma patients undergoing repeated cycles of the CHOP regimen. *Support Care Cancer*.2018;26(1):269-274.
6. Mukhopadhyay S, Kwatra G, Alice K P, Badyal D. Role of olanzapine in chemotherapy-induced nausea and vomiting on platinum-based chemotherapy patients: a randomized controlled study. *Support Care Cancer*.2017;25(1):145-154.
7. Hayashi T, Shimokawa M, Miyoshi T, et al. A prospective, observational, multicenter study on risk factors and prophylaxis for low emetic risk chemotherapy-induced nausea and vomiting. *Support Care Cancer* 2017;25(9):2707-2714.
8. Schwartzberg LS, Marks SM, Gabrail NY, et al. Real-world effectiveness of palonosetron-based antiemetic regimens: preventing chemotherapy-induced nausea and vomiting. *J Comp Eff Res*. 2019; 8(9): 657-670.
9. Campos GO, Martins MDJ, Jesus GN, et al. Palonosetron versus ondansetron for prevention of nausea and vomiting after total abdominal hysterectomy under spinal anesthesia with intrathecal morphine: a double-blind, randomized controlled trial. *BMC Anesthesiol*.2019;19 (159):1-6.
10. Kramer L, Trinkman H, Arrowood R, and Ray A. Impact of a reduced palonosetron maximum dose on the incidence of chemotherapy-induced nausea and vomiting in pediatric patients.*Authorea*. 2021. DOI: 10.22541/au.162395520.08447874/v1
11. Palonosetron In: AHFS Drug Information Online Electronic Medical Library. Bethesda, MD: American Society of Health-System Pharmacists. Updated March 4, 2019.